Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEARNS study of levamisole added to prednisolone to prevent relapse in first-episode steroid-sensitive idiopathic nephrotic syndrome in children
2024-517467-23-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) comparing Levamisole plus prednisolone with Placebo plus prednisolone (2 arms). Primary endpoint: Occurrence of relapses within 12 months after first presentation. Planned start Nov 2024; status: authorised.
02
Drugs
levamisole
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2024-517467-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517467-23-00.